Duloxetine in the treatment of major depressive disorder: an open-label study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-244X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Duloxetine in the treatment of major depressive disorder: an open-label study ; volume:7 ; number:1 ; day:28 ; month:8 ; year:2007 ; pages:1-11 ; date:12.2007
BMC psychiatry ; 7, Heft 1 (28.8.2007), 1-11, 12.2007
- Urheber
-
Hudson, James I.
- Beteiligte Personen und Organisationen
-
Perahia, David G.
Gilaberte, Inmaculada
Wang, Fujun
Watkin, John G.
Detke, Michael J.
SpringerLink (Online service)
- DOI
-
10.1186/1471-244X-7-43
- URN
-
urn:nbn:de:1111-2016030425104
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hudson, James I.
- Perahia, David G.
- Gilaberte, Inmaculada
- Wang, Fujun
- Watkin, John G.
- Detke, Michael J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Agomelatine in pediatric patients with moderate to severe major depressive disorder: an open-label extension study
An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)
Duloxetine for the long-term treatment of Major Depressive Disorder in patients aged 65 and older: an open-label study
Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder
Aripiprazole in Children and Adolescents with Conduct Disorder: A Single-Center, Open-Label Study
Vortioxetine in children and adolescents with major depressive disorder: 6-month and 18-month open-label, flexible-dose, long-term extension studies
Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study
Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study
IGF-1 in autosomal dominant cerebellar ataxia - open-label trial
Effects of practicing yoga on alexisomia: an open-label trial
An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder
Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study
Agomelatine in pediatric patients with moderate to severe major depressive disorder: an open-label extension study
An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)
Duloxetine for the long-term treatment of Major Depressive Disorder in patients aged 65 and older: an open-label study
Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder
Aripiprazole in Children and Adolescents with Conduct Disorder: A Single-Center, Open-Label Study
Vortioxetine in children and adolescents with major depressive disorder: 6-month and 18-month open-label, flexible-dose, long-term extension studies
Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study
Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study
IGF-1 in autosomal dominant cerebellar ataxia - open-label trial
Effects of practicing yoga on alexisomia: an open-label trial
An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder
Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study
Agomelatine in pediatric patients with moderate to severe major depressive disorder: an open-label extension study
An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)
Duloxetine for the long-term treatment of Major Depressive Disorder in patients aged 65 and older: an open-label study
Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder
Aripiprazole in Children and Adolescents with Conduct Disorder: A Single-Center, Open-Label Study
Vortioxetine in children and adolescents with major depressive disorder: 6-month and 18-month open-label, flexible-dose, long-term extension studies
Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study
Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study
IGF-1 in autosomal dominant cerebellar ataxia - open-label trial
Effects of practicing yoga on alexisomia: an open-label trial
An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder